Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Centene Corp (CNC) vs KLA Corp. (KLAC) Price & Performance

Centene CorpTrade

Price performance (Past 24H)

Key statistics

Centene Corp vs KLA Corp. — how do they compare? Centene Corp trades at $65.11 (market cap $32.05B), while KLA Corp. trades at $208.04 (market cap $261.92B). The key difference: KLA Corp. is far larger — about 8.2× Centene Corp's market cap, and KLA Corp. pays a 0.46% dividend while Centene Corp pays none. Which is the better fit depends on your goals.

CNCKLAC
Market Cap
$32.05B$261.92B
Sector
HealthTechnology
52-Week High
$68.72$301.71
52-Week Low
$26.17$84.39
Enterprise Value
$21.10B$263.17B
Dividend Yield
0.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Centene Corp

Centene (CNC) trades at $66.56, up 1.2% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $71.00. The company reported strong Q2 2026 earnings of $2.51 per share, beating estimates, and raised its full-year EPS guidance, reflecting margin recovery and cost discipline. Revenue growth remains robust, projected to reach $202.9 billion in 2026, though net income margins are negative due to elevated medical costs.

The stock presents a value opportunity with low P/E (8.06) and P/S (0.16) ratios, but investors face risks from Medicaid membership volatility and regulatory pressures. Analyst sentiment is strongly bullish (61% buy ratings), with institutional interest growing, as seen in recent fund additions. Near-term upside is likely if cost controls sustain profitability improvements.

KLA Corp.

KLA Corporation (KLAC) trades at $192.74, down 2.71% on the day, amid a broader semiconductor sector pullback. The stock shows strong fundamentals with revenue growth to $12.16B in 2025 and net income of $4.06B, though valuation ratios remain elevated with a P/E of 54.77. Recent corporate actions include a 1:10 stock split and dividend declarations, while technical indicators signal near-term bearish pressure with key support at $189.

KLAC presents a compelling long-term investment case driven by AI-driven semiconductor equipment demand and consistent earnings beats, but faces risks from high valuation and sector volatility. Analyst consensus remains bullish with a $246.93 price target implying 28% upside, though investors should monitor execution against growth expectations and competitive dynamics in the semiconductor equipment space.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Centene Corp

Centene is a managed-care organization focused on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 22 million medical members as of September 2021, mostly in Medicaid (68% of membership), the individual exchanges (10%), Medicare Advantage (6%), and the balance in Tricare (West region), correctional facility, and international plans. The company also serves 4 million users through the Medicare Part D pharmaceutical program.

Read more on CNC

About KLA Corp.

KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.

Read more on KLAC